CTLA4 and melanoma: As an example, the combination therapy of immune checkpoint inhibitors, particularly the administration of both anti-CTLA-4 and anti-PD-1 agents (ipilimumab and nivolumab), yields the highest 5-year overall survival rates in advanced melanoma.